

IN THE CLAIMS:

1. (original) A liposome to which a polyalkylene glycol and albumin are bonded.

2. (original) The liposome according to claim 1, wherein a physiologically active ingredient is further contained.

3. (original) The liposome according to claim 2, wherein the physiologically active ingredient is a pharmaceutically active ingredient.

4. (original) The liposome according to claim 3, wherein the pharmaceutically active ingredient is an antitumor agent.

5. (currently amended) A pharmaceutical composition containing the liposome mentioned in ~~any one of claims 2 to 4~~ claim 2.

6. (original) The pharmaceutical composition according to claim 5, which is an injection.


7. (original) A method for treatment of cancer, which comprises administering a pharmaceutical composition comprising a

liposome to which a polyalkylene glycol and albumin are bonded and in which an antitumor agent is contained.

8. (currently amended) ~~Use of~~ A method of extending the in vivo retention time of a physiologically active ingredient contained in a liposome to which comprising binding the liposome to a polyalkylene glycol and albumin are bonded and in which a physiologically active ingredient is contained, for the extension of the in vivo retention time of the physiologically active ingredient.

9. (original) A process for the production of the liposome of claim 1, characterized in that,


a liposome having a compound represented by the following formula (1):




(1)

(wherein R is an acyl group derived from a fatty acid having 2 to 35 carbon atoms) as a constituent lipid is bonded to albumin;

a liposome having a compound represented by the following formula (2):




(wherein R has the same meaning as defined above) as a constituent lipid is bonded to a compound represented by the formula (3):




(wherein Alb-NH is a group formed by removing one hydrogen atom of the amino group from an albumin molecule represented by Alb-NH₂);

a liposome having a compound represented by the following formula (4):



(4)

(wherein n is an integer of 5 to 100,000 and R has the same meaning as defined above) as a constituent lipid is bonded to a compound represented by the formula (5):



(wherein Alb-NH has the same meaning as defined above);

a compound represented by the following formula (6):




a liposome having the compound represented by the above formula (1) as a constituent lipid is bonded to a compound represented by the following formula (7):



P:\05-05\iwt-001-pto-pre-amd.wpd

above); or

a liposome having the compound represented by the above formula (2) as a constituent lipid is bonded to a compound represented by the following formula (8):



(8)

(wherein ---NH-Alb-NH--- is a group formed by removing one hydrogen atom from each of the two amino groups of an albumin molecule represented by the formula $\text{H}_2\text{N-Alb-NH}_2$, and n has the same meaning as defined above).

10. (new) A pharmaceutical composition containing the liposome mentioned in claim 3.

11. (new) A pharmaceutical composition containing the liposome mentioned in claim 4.

12. (new) The pharmaceutical composition according to claim 10, which is an injection.

13. (new) The pharmaceutical composition according to claim 11, which is an injection.